The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound ...

Last week, Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition in which breathing stops and starts repeatedly during sleep ...

But the program may be able to cover an obesity medication that treats a secondary condition, like obstructive sleep apnea. Scientists are studying weight loss drugs for a broad array of ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Weight loss drug found in Mounjaro for use in sleep apnea patients approved by FDA 02:53. Weight loss drugs known as GLP1s are all the rage right now.

And if taken for weight loss, the drug will likely be taken for life. But Malhotra says research is still out on whether the same goes for treating sleep apnea. Report a correction or typo ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Last week, Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition in which breathing stops and starts repeatedly during sleep.

Even before the FDA approval, some doctors have been prescribing weight-loss drugs to people with sleep apnea. The FDA’s decision may place added pressure on insurance companies to cover obesity ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...